Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 222Carcinoma, Renal Cell 84Liver Neoplasms 68Neoplasms 53Leukemia, Myeloid, Acute 37Neoplasm Metastasis 34Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 29Melanoma 24Kidney Neoplasms 22Pancreatic Neoplasms 16Brain Neoplasms 15Sarcoma 14Prostatic Neoplasms 14Lung Neoplasms 14Thyroid Neoplasms 13Recurrence 13Glioblastoma 13Colorectal Neoplasms 12Carcinoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Urinary Bladder Neoplasms 8Rectal Neoplasms 8Ovarian Neoplasms 8Myelodysplastic Syndromes 8Multiple Myeloma 8Gliosarcoma 8Stomach Neoplasms 7Colonic Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6

Interventions

Gemcitabine 6Cisplatin 6Capecitabine 6Liver Transplantation 4Fluorouracil 4Specimen Handling 3Radiosurgery 3Oxaliplatin 3Magnetic Resonance Spectroscopy 3toripalimab 2dehydroftorafur 2Self Expandable Metallic Stents 2Platinum 2Leucovorin 2Biopsy 23-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 21,2-diaminocyclohexaneplatinum II citrate 2trisacryl gelatin microspheres 1tremelimumab 1trametinib 1tislelizumab 1temoporfin 1sacituzumab govitecan 1ricolinostat 1pembrolizumab 1lenvatinib 1gemcitabine-oxaliplatin regimen 1fludarabine 1durvalumab 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Klatskin Tumor × Sorafenib × Clear all
NCT01093222 2015-06-30

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled 16 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡